This week, the overall grades of 16 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Intercept Pharmaceuticals, Inc.’s (ICPT) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

Alnylam Pharmaceuticals, Inc (ALNY) experiences a ratings drop this week, going from last week’s C to a D. Alnylam Pharmaceuticals, Inc engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ALNY stock.

AbbVie, Inc. (ABBV) gets weaker ratings this week as last week’s C drops to a D. AbbVie, Inc. a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

This is a rough week for Enanta Pharmaceuticals, Inc. (ENTA). The company’s rating falls to D from the previous week’s C. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENTA stock.

This week, Genomic Health, Inc. (GHDX) drops from a D to a F rating. Genomic Health, Inc. is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

Adamas Pharmaceuticals, Inc. (ADMS) slips from a C to a D this week. The company also gets F’s in sales growth, operating margin growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ADMS stock.

Tokai Pharmaceuticals, Inc. (TKAI) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TKAI stock.

Regulus Therapeutics Inc. (RGLS) is having a tough week. The company’s rating falls from a C to a D. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

Argos Therapeutics, Inc. (ARGS) earns a D this week, moving down from last week’s grade of C. Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARGS stock.

Slipping from a C to a D rating, Spectrum Pharmaceuticals, Inc. (SPPI) takes a hit this week. Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of SPPI stock.

CareDx, Inc.’s (CDNA) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of CDNA stock.

This week, Orexigen Therapeutics, Inc.’s (OREX) rating worsens to a D from the company’s C rating a week ago. Orexigen Therapeutics, Inc. is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system disorders with an initial focus on obesity. For more information, get Portfolio Grader’s complete analysis of OREX stock.

QLT Inc. (QLTI) is having a tough week. The company’s rating falls from a D to a F. QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of QLTI stock.

Vericel Corporation (VCEL) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings momentum and free cash flow. For more information, get Portfolio Grader’s complete analysis of VCEL stock.

Biota Pharmaceuticals, Inc. (BOTA) experiences a ratings drop this week, going from last week’s C to a D. Biota Pharmaceuticals, Inc. is an anti-infective drug development company with expertise in respiratory diseases, particularly influenza. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BOTA stock.

Slipping from a C to a D rating, IsoRay, Inc. (ISR) takes a hit this week. IsoRay, Inc. produces a brachytherapy seed, used to treat prostate and other cancers. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of ISR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.